Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: J Thorac Oncol. 2019 Mar 1;14(5):802–815. doi: 10.1016/j.jtho.2018.12.038

FIGURE 5. The pan-RAF inhibitor LY3009120 effectively inhibits growth of EGFR mutant cell lines with BRAF fusions.

FIGURE 5.

A. Cells were plated in 96-well plates, treated with LY3009120 and then growth determined (Left). IC50 values for growth inhibition were determined by nonlinear regression analysis using GraphPad Prism software (Right). B. MSK-LX138cl cells were treated with the indicated concentration of LY3009120 or vemurafenib for 1 h then whole-cell extracts prepared and immunoblotted for the indicated proteins. Results are representative of two independent experiments. C. Cells were treated with 0.1 or 1 μM of the indicated compounds or osimertinib/trametinib combinations and caspase 3/7 activity determined 48 h later.